瑞舒伐他汀与奥利司他对老年肥胖型高血脂患者的疗效分析
|
摘要
目的探究瑞舒伐他汀钙与奥利司他对老年肥胖型高血脂患者的治疗效果。方法选取2018年1月～6月我院收治的老年肥胖型高血脂患者110例作为研究对象,将其随机分为对照组和观察组,各55例,对照组给予瑞舒伐他汀钙治疗,观察组在对照组基础上加服奥利司他,关察两组患者治疗前后体重、BMI指数、血脂水平和不良反应。结果治疗后两组患者体重、BMI指数均有所下降,观察组下降优势更明显(P<0.05),观察组TC、TG、HDL-C和LDL-C水平均有所好转,均优于对照组(P<0.05);观察组四类不良反应发生率均明显低于对照组(P<0.05),安全性更高。结论瑞舒伐他汀与奥利司他联合治疗老年肥胖型高血脂症能够降低患者体质指数,临床疗效确切,安全性高,可以进行推广应用。
Objective To investigate the therapeutic effects of rosuvastatin calcium and orlistat on elderly obese hyperlipidemia patients.Methods 110 elderly obese hyperlipidemia patients admitted to our hospital from January to June 2018 were randomly divided into control group and observation group, 55 cases each. The control group was treated with rosuvastatin calcium. The observation group was based on the control group, Orlistat was added, to observe the body weight, BMI index, blood lipid level and adverse reactions before and after treatment.Results After treatment, the body weight and BMI index of the two groups were decreased, and the decline of the observation group was more obvious(P<0.05). The levels of TC, TG, HDL-C and LDL-C in the observation group improved, which were better than the control group(P<0.05). The incidence of four types of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). More secure.Conclusion The combination of rosuvastatin and orlistat in the treatment of obese hyperlipidemia can reduce the body mass index of patients, and the clinical efficacy is high and the safety is high, which can be promoted and applied.
Objective To investigate the therapeutic effects of rosuvastatin calcium and orlistat on elderly obese hyperlipidemia patients.Methods 110 elderly obese hyperlipidemia patients admitted to our hospital from January to June 2018 were randomly divided into control group and observation group, 55 cases each. The control group was treated with rosuvastatin calcium. The observation group was based on the control group, Orlistat was added, to observe the body weight, BMI index, blood lipid level and adverse reactions before and after treatment.Results After treatment, the body weight and BMI index of the two groups were decreased, and the decline of the observation group was more obvious(P<0.05). The levels of TC, TG, HDL-C and LDL-C in the observation group improved, which were better than the control group(P<0.05). The incidence of four types of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05). More secure.Conclusion The combination of rosuvastatin and orlistat in the treatment of obese hyperlipidemia can reduce the body mass index of patients, and the clinical efficacy is high and the safety is high, which can be promoted and applied.
引文
[1]吴宝,许国磊,谢相智,等.奥利司他联合瑞舒伐他汀治疗单纯性肥胖伴高脂血症患者的疗效分析[J].中国循证心血管医学杂志,2017,9(7):845-847.
[2]熊伟平,边长勇.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂炎性介质及内皮指标的影响[J].山西医药杂志,2017,46(23):2909-2911.
[3]王环宇.瑞舒伐他汀对冠心病合并高脂血症老年病人血脂和炎症因子水平的影响[J].中西医结合心脑血管病杂志,2016,14(21):2515-2518.
[4]丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044
[5]董其坤瑞舒伐他汀治疗高血脂症合并颈动脉粥样硬化患者的临床效果[J].实用临床医药杂志,2016,20(3):21-24.
[6]蒋晓发.不同剂量瑞舒伐他汀对老年冠心病合并高脂血症患者的疗效分析[J].国际老年医学杂志,2017,38(3):108-111.
[7]靳宏举,李红云.不同剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效对比[J].实用心脑肺血管病杂志,2016,15(04):72-72.
[8]黎晓亮,兰群芳,陆妙,等.奥利司他联合非诺贝特治疗肥胖伴脂质代谢紊乱的疗效分析[J].中国医院药学杂志学术年会,2016,11(8):156-158.
[9]张盈妍,沈静雪,杨立新,等.膳食疗法联合奥利司他治疗内分泌失调性肥胖患者的疗效探讨[J].中国现代药物应用,2017,11(1):137-138.
[10]刘永健,李凌鸥,程菲菲.奥利司他对比二甲双胍降低超体质量或肥胖患者体质量疗效和安全性的Meta分析[J].中国药房,2018,12(5):690-694.
[2]熊伟平,边长勇.瑞舒伐他汀治疗冠心病伴高脂血症的疗效及其对血脂炎性介质及内皮指标的影响[J].山西医药杂志,2017,46(23):2909-2911.
[3]王环宇.瑞舒伐他汀对冠心病合并高脂血症老年病人血脂和炎症因子水平的影响[J].中西医结合心脑血管病杂志,2016,14(21):2515-2518.
[4]丁晓虎,李彩云,丁峰.依折麦布联合瑞舒伐他汀治疗冠心病患者血脂异常的疗效与安全性的Meta分析[J].江苏医药,2016,42(9):1042-1044
[5]董其坤瑞舒伐他汀治疗高血脂症合并颈动脉粥样硬化患者的临床效果[J].实用临床医药杂志,2016,20(3):21-24.
[6]蒋晓发.不同剂量瑞舒伐他汀对老年冠心病合并高脂血症患者的疗效分析[J].国际老年医学杂志,2017,38(3):108-111.
[7]靳宏举,李红云.不同剂量瑞舒伐他汀钙治疗老年冠心病合并高脂血症的疗效对比[J].实用心脑肺血管病杂志,2016,15(04):72-72.
[8]黎晓亮,兰群芳,陆妙,等.奥利司他联合非诺贝特治疗肥胖伴脂质代谢紊乱的疗效分析[J].中国医院药学杂志学术年会,2016,11(8):156-158.
[9]张盈妍,沈静雪,杨立新,等.膳食疗法联合奥利司他治疗内分泌失调性肥胖患者的疗效探讨[J].中国现代药物应用,2017,11(1):137-138.
[10]刘永健,李凌鸥,程菲菲.奥利司他对比二甲双胍降低超体质量或肥胖患者体质量疗效和安全性的Meta分析[J].中国药房,2018,12(5):690-694.